4.8 Article

CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 131, Issue 22, Pages -

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI153285

Keywords

-

Funding

  1. NIH [R35HL150754, P01HL151328, R01HL45095]
  2. American Heart Association [20CDA35320109]
  3. American Diabetes Association [9-18-CVD1-002]
  4. National Lipid Association
  5. N. Berrie Foundation
  6. Vector and Transgenic Mouse Core, Diabetes Research Center at University of Washington (NIH) [P30DK017047]
  7. University of Washington Nutrition and Obesity Research Center (NIH) [P30DK035816]

Ask authors/readers for more resources

Loss-of-function mutations in CREBH are associated with severe hypertriglyceridemia in humans, but in a mouse model of T1DM, increased liver expression of active CREBH normalized elevated plasma triglycerides and cholesterol levels. APOE plays a critical role in CREBH’s ability to reduce circulating remnant lipoproteins, and elevated levels of remnants may contribute to the pathogenesis of atherosclerosis in T1DM.
Loss-of-function mutations in the transcription factor CREB3L3 (CREBH) associate with severe hypertriglyceridemia in humans. CREBH is believed to lower plasma triglycerides by augmenting the activity of lipoprotein lipase (LPL). However, by using a mouse model of type 1 diabetes mellitus (T1DM), we found that greater liver expression of active CREBH normalized both elevated plasma triglycerides and cholesterol. Residual triglyceride-rich lipoprotein (TRL) remnants were enriched in apolipoprotein E (APOE) and impoverished in APOC3, an apolipoprotein composition indicative of increased hepatic clearance. The underlying mechanism was independent of LPL, as CREBH reduced both triglycerides and cholesterol in LPL-deficient mice. Instead, APOE was critical for CREBH's ability to lower circulating remnant lipoproteins because it failed to reduce TRL cholesterol in Apoe(-/-) mice. Importantly, individuals with CREB3L3 loss-of-function mutations exhibited increased levels of remnant lipoproteins that were deprived of APOE. Recent evidence suggests that impaired clearance of TRL remnants promotes cardiovascular disease in patients with T1DM. Consistently, we found that hepatic expression of CREBH prevented the progression of diabetes-accelerated atherosclerosis. Our results support the proposal that CREBH acts through an APOEdependent pathway to increase hepatic clearance of remnant lipoproteins. They also implicate elevated levels of remnants in the pathogenesis of atherosclerosis in T1DM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available